Fig. 8: CA-mediated inhibition of CEBPβ/NFκB signalling directly inhibits BACE1. | Cell Death & Disease

Fig. 8: CA-mediated inhibition of CEBPβ/NFκB signalling directly inhibits BACE1.

From: Inhibition of the CEBPβ-NFκB interaction by nanocarrier-packaged Carnosic acid ameliorates glia-mediated neuroinflammation and improves cognitive function in an Alzheimer’s disease model

Fig. 8

A Representative blots of NFκB p65 in SH-SY5Y cells following transfection with a lentiviral vector-encoding human CEBPβ (LV-CEBPβ) or treatment with LV-CEBPβ plus CA. B The DNA binding activity of NFκB was determined by ELISA. C IF staining shows the NFκB p65 (green) and CEBPβ (red) protein expressions. Scale bars: 20 µm. D FCM analysis of NFκB p65 (FITC channel) and CEBPβ (PE channel) after treatment with LV-CEBPβ or LV-CEBPβ plus CA. E The binding of CEBPβ to NFκB was examined by Co-IP. F Similar to JSH-23, CA treatment-induced decreases in nuclear NFκB p65 and cytosolic BACE1 expressions were blocked by LV-CEBPβ. G CA-mediated inhibition of BACE1 was diminished by the NFκB activator, PMA. The data were representative of at least three independent experiments. **p < 0.01 and ***p < 0.001 vs the controls; ##p < 0.01 vs the LV-CEBPβ-treated group (A–E). **p < 0.01 and ***p < 0.001 vs the controls; ###p < 0.001 versus CA-treated group; $$$p < 0.001 versus JSH-23 treatment group (F). **p < 0.01 vs the controls; ##p < 0.01 vs the CA treatment group (G). Data were analysed using one-way ANOVA and Fisher LSD post hoc tests. Values represent the mean ± SD of at least three independent experiments.

Back to article page